# US 12,005,233 B2 · Automated system for monitoring a patient's blood sugar

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,233 B2
- Document ID: US12005233B2
- Status: Granted
- Kind: B2
- Application number: 17/057,632
- Filed: 2019-05-03
- Published: 2021-08-26
- Granted: 2024-06-11
- Earliest claimed: 2018-05-22
- Assignees: Commissariat A L'energie Atomique Et Aux Energies Alternatives
- Applicants: Commissariat à l'Énergie Atomique et aux Énergies Alternatives
- Inventors: Romain Blanc; Eléonore-Maeva Doron; Hector-Manuel Romero Ugalde
- Web page: https://patentgrep.com/patent/US12005233B2

## CPC

- A61B 5/4839: {combined with drug delivery}
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61B 5/1118: {Determining activity level}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G16H 20/17: delivered via infusion or injection
- G16H 50/50: for simulation or modelling of medical disorders
- A61B 5/024: Measuring pulse rate or heart rate
- A61B 5/4866: {Evaluating metabolism (using breath test A61B5/083)}
- A61B 2562/0219: Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
- A61M 2205/502: User interfaces, e.g. screens or keyboards
- A61M 2205/702: automatically during use
- A61M 2230/06: Heartbeat rate only
- A61M 2230/201: Glucose concentration
- A61M 2230/63: Motion, e.g. physical activity
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

An automated system for controlling a patient's blood glucose, including a blood glucose sensor, a device for measuring a physical activity of the patient, and a processing and control unit, wherein: the processing and control unit is configured to generate, by convolution of a signal PA supplied by the device for measuring a physical activity of the patient with a decreasing mathematical function H, a signal IPA representative of the influence of the patient's physical activity on his/her insulin sensitivity; and the processing and control unit is configured to calculate, from a first patient-specific mathematical model fCR and taking into account signal IPA and from a single blood glucose value Gr measured by the sensor, a factor CR representative of the patient's insulin sensitivity.

## Claims

### Claim 1

An automated system for controlling a patient's blood glucose, comprising a blood glucose sensor, a device for measuring a physical activity of a patient, and a processing and control unit, wherein:
the processing and control unit is configured to generate, by convolution of a signal PA supplied by the device for measuring a physical activity of the patient with a decreasing mathematical function H, a signal IPA representative of the influence of the patient's physical activity on his/her insulin sensitivity; and
the processing and control unit is configured to calculate, from a first patient-specific mathematical model fCR and taking into account signal IPA and from a single blood glucose value Gr measured by the sensor, a factor CR representative of the patient's insulin sensitivity.

### Claim 2 (depends on 1)

The system according to claim 1, further comprising an insulin injection device, wherein the processing and control unit is configured to control the insulin injection device by taking into account factor CR.

### Claim 3 (depends on 2)

The system according to claim 2, wherein the processing and control unit is configured to predict, from a second mathematical model, the future trend of the patient's blood glucose over a prediction period, and to control the insulin injection device by taking the prediction into account.

### Claim 4 (depends on 1)

The system according to claim 1, in the first mathematical model is a function of equation
CR=ƒCR(IPA,Gr)=α×IPAb+c×Grd+e
where a, b, c, d, and e are patient-specific parameters.

### Claim 5 (depends on 1)

The system according to claim 1, wherein the first mathematical model is a function of equation
CR=Gr׃R(IPA)=Gr×(α×IPAb+c)
where a, b, and c are patient-specific parameters.

### Claim 6 (depends on 1)

The system according to claim 1, wherein the processing and control unit is configured to implement a step of automatic calibration of first model fCR by taking into account a history of the blood glucose measured by the sensor, a history of insulin injected to the patient, a history of carbohydrate ingestion by the patient, and a history of the patient's physical activity signal PA over a past observation period.

### Claim 7 (depends on 6)

The system according to claim 6, wherein the processing and control unit is configured to, during the automatic calibration step, measure a plurality of values of the patient's real insulin sensitivity factor CRr during a plurality of measurement events contained in the past observation period.

### Claim 8 (depends on 7)

The system according to claim 7, wherein each measurement event corresponds to a continuous time range from an initial time tinit to a final time tfinal, complying with the following criteria:
time tinit is in a hyperglycemia phase, that is, a phase where the patient's blood glucose is greater than a predetermined threshold;
a correction bolus, that is, an additional insulin dose has been delivered to the patient after the beginning of the hyperglycemia phase and before time tinit, to limit the duration of the hyperglycemia phase;
the patient's blood glucose continuously decreases between initial time tinit and final time tfinal; and
no carbohydrate ingestion by the patient has occurred between time tinit−Tj and time tfinal, where Tj is a predetermined fasting duration.

### Claim 9 (depends on 7)

The system according to claim 7, wherein the processing and control unit is configured to, during the automatic calibration step, determine the first mathematical model fCR by regression from said plurality of values of the real insulin sensitivity factor CRr.

### Claim 10 (depends on 1)

The system of claim 1, wherein function H is a decreasing exponential function.

### Claim 11 (depends on 1)

The system according to claim 1, wherein the measurement device comprises a user interface via which the patient declares his/her physical activities.

### Claim 12 (depends on 1)

The system according to claim 1, wherein the measurement device comprises one or a plurality of sensors capable of measuring quantities representative of the patient's physical activity.

### Claim 13 (depends on 12)

The system according to claim 12, wherein the measurement device comprises a motion sensor and/or a heart rate sensor.